5 dengue vaccines in development

Tuesday, September 8, 2015

Currently, there are no approved vaccines or therapies to prevent dengue infection. The disease, which primarily affects children, is associated with approximately 22,000 deaths annually worldwide, according to the CDC.

Infectious Disease News has compiled information on five candidate dengue vaccines in various stages of development: V180, Merck — phase 1; TDENV PIV, GlaxoSmithKline and Walter Reed Army Institute of Research — phase 1 and phase 2; TV003, NIAID — phase 2; DENVax, Takeda — phase 2 and phase 2b; and CYD-TDV, Sanofi Pasteur — phase 3.

The Sanofi vaccine is the furthest along in development; however, it may only work for older patients and limit its use. However, because of its overall efficacy, CYD-TDV can still significantly reduce the massive burden of dengue, for which 40 percent of the world lives in at-risk areas.

Source: Infectious Disease News (link opens in a new window)

Health Care
infectious diseases, vaccines